Narrative review uncovers viral triggers and immune pathways in myasthenia gravis, indicating potential pathogen-targeted therapeutic strategies.
Myasthenia gravis (MG) is a chronic autoimmune disorder that involves the targeting of neuromuscular junctions and is primarily driven by autoantibodies against the acetylcholine receptor (AChR). While genetic susceptibility is a factor, environmental triggers, particularly viral infections, are being increasingly investigated as potential contributors to MG pathogenesis. This review examines the complex interplay between viral pathogens and MG, highlighting mechanisms such as molecular mimicry, bystander activation, and the aberrant stimulation of innate immune pathways via Toll-like receptors (TLRs). Key DNA viruses, including Epstein‒Barr virus (EBV) and parvovirus B19, have been detected within hyperplastic thymic tissues and thymomas, suggesting that they may sustain local autoreactive B-cell activation. Furthermore, recent clinical data emphasize the role of RNA viruses, most notably SARS-CoV-2, as significant triggers of new-onset MG and myasthenic crises. Despite substantial evidence linking viral infections to MG, further mechanistic research and large-scale observational studies are needed to definitively establish causality and refine therapeutic strategies targeting these virus-induced immune responses.
No takes yet. Share an insight, caveat, or question.
Dolci et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: